MedTrace Logo

Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

NCT00006656 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-11-06

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of carmustine in treating patients who have progressive or recurrent glioblastoma multiforme.

Conditions

Interventions

DRUG

carmustine in ethanol

PROCEDURE

conventional surgery

Sponsors & Collaborators

  • Direct Therapeutics

    lead INDUSTRY

Principal Investigators

  • Gene David Resnick, MD · Millennix

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006656 on ClinicalTrials.gov